Brain scans reveal how new combo drug curbs appetite

NCT ID NCT06267092

Completed Symptom relief Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 study tested how CagriSema (a combination of cagrilintide and semaglutide) affects appetite and brain activity in 164 adults with overweight or obesity. Participants received either the drug, a placebo, or no medicine, and researchers measured appetite scores and brain responses using scans. The goal was to understand the mechanisms behind appetite control, not to achieve weight loss directly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CagriSema (cagrilintide and semaglutide combination)
What this could lead to: If it works, this could help explain how this combination medicine reduces appetite and changes brain activity, potentially leading to better weight-loss treatments.
What could go wrong: This is an early Phase 1 study focused on measuring appetite and brain signals, not weight loss itself. Results may not translate to long-term benefits or apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Locations

Charité - Campus Charité Mitte - Charité Research Organisation GmbH

Berlin, 10117, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.